Exciva GmbH Raises €51 Million Series B to Advance Phase 2 Program for Alzheimer’s Agitation Therapy

Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closi...

January 22, 2026 | Thursday | News
Bayer and Vanderbilt University Medical Center Form Five-Year Strategic Collaboration to Advance Innovative Therapies

-Bayer and Vanderbilt University Medical Center (VUMC) announced that they have entered a strategic five-year collaboration agreement to advance innovati...

January 21, 2026 | Wednesday | News
ImmunityBio’s CAR-NK Program Delivers Durable Responses Without Chemotherapy in Rare B-Cell Lymphoma

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced updated efficacy and safety results from the ongoing QUILT-106 clin...

January 20, 2026 | Tuesday | News
AGC Biologics’ Milan Cell and Gene Center Strengthens Global Leadership with Waskyra™ Approval

This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved ...

January 20, 2026 | Tuesday | News
Daiichi Sankyo and AstraZeneca Secure EMA Validation for ENHERTU Combination in First-Line HER2-Positive Metastatic Breast Cancer

Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significant...

January 20, 2026 | Tuesday | News
AbbVie and Genmab Report Positive PFS Results from Phase 3 EPCORE® DLBCL-1 Trial of Epcoritamab in Relapsed/Refractory DLBCL

Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss ...

January 19, 2026 | Monday | News
Atossa Therapeutics Secures FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy

Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pedi...

January 19, 2026 | Monday | News
Swissmedic Approves Santhera’s AGAMREE® for Duchenne Muscular Dystrophy

Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE® (vamorolone) for th...

January 16, 2026 | Friday | News
Stablepharma and AFT Pharmaceuticals Partner to Develop Fridge-Free Sterile Injectables for Global Markets

  Stablepharma Limited, specialists in thermostable formulations,announced a development and option-to-license agreement with AFT Pharmaceuticals to ...

January 16, 2026 | Friday | News
Rakuten Medical Partners With LOTTE Biologics to Expand Manufacturing for Alluminox® Photoimmunotherapy

  Rakuten Medical, Inc. and LOTTE Biologics announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P....

January 15, 2026 | Thursday | News
ElpasBio Partners With Fosun Kairos to Commercialize AlloJoin® Stem Cell Therapy for Knee Osteoarthritis in Greater China

ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, announced that it has entered into a col...

January 15, 2026 | Thursday | News
Cellistic Expands Echo™ Platform Portfolio With Three New GMP iPSC-Derived Cell Therapy Manufacturing Platforms

Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy m...

January 15, 2026 | Thursday | News
Hongene Biotech Secures Gates Foundation Grant to Advance Equitable mRNA Vaccine Manufacturing

Hongene Biotech announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use ...

January 14, 2026 | Wednesday | News
Lilly Bets on Chronic Inflammation With $1.2B All-Cash Acquisition of Ventyx

Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on...

January 11, 2026 | Sunday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close